Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy

European Journal of Pharmacology

Volumn 614, Issue 1-3, 2009, Pages 30-37

  Matagne, Alain ^a   Margineanu, Doru Georg ^a   Potschka, Heidrun ^b   Löscher, Wolfgang ^b   Michel, Philippe ^a   Kenda, Benoit ^a   Klitgaard, Henrik ^a  

^a UCB PHARMA   (Belgium)

^b UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Anti seizure effect; Antiepileptic effect; Levetiracetam; Safety profile; Seletracetam; SV2A; Synaptic vesicle protein

Indexed keywords

CALCIUM ION; ETHOSUXIMIDE; ETIRACETAM; POTASSIUM ION; SELETRACETAM; VALPROIC ACID;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUDIOGENIC SEIZURE; CLONIC SEIZURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; EPILEPSY; EPILEPTIC DISCHARGE; FEMALE; GRAND MAL SEIZURE; HIPPOCAMPUS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; ROTAROD TEST; SEIZURE THRESHOLD;

AMYGDALA; ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; EPILEPSY; FEMALE; HIPPOCAMPUS; MALE; MICE; MOTOR ACTIVITY; PYRROLIDINONES; RATS; RATS, SPRAGUE-DAWLEY; ROTAROD PERFORMANCE TEST; SEIZURES;

EID: 67349156665     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.04.024     Document Type: Article

References (22)

1. Andersen P., Bliss T.V., and Skrede K.K. Unit analysis of hippocampal polulation spikes. Exp. Brain Res. 13 (1971) 208-221
2. Gower A.J., Noyer M., Verloes R., Gobert J., and Wulfert E. Ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur. J. Pharmacol. 222 (1992) 193-203
3. Gower A.J., Hirsch E., Boehrer A., Noyer M., and Marescaux C. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res. 22 (1995) 207-213
4. Kaminski R.M., Matagne A., Leclercq K., Gillard M., Michel P., Kenda B., Talaga P., and Klitgaard H. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 54 (2008) 715-720
5. Kenda B.M., Matagne A.C., Talaga P.E., Pasau P.M., Differding E., Lallemand B.I., Frycia A.M., Moureau F.G., Klitgaard H.V., Gillard M.R., Fuks B., and Michel P. Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. J. Med. Chem. 47 (2004) 530-549
6. Klitgaard H., and Matagne A. Mechanisms of action of levetiracetam and newer SV2A ligands. In: Shorvon S., and Pedley T.A. (Eds). The Epilepsies. Blue Books of Neurology vol. 3 (2009), Saunders Elsevier 27-38
7. Klitgaard H., Matagne A., Gobert J., and Wulfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol. 353 (1998) 191-206
8. Löscher W., and Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res. 2 (1988) 145-181
9. Löscher W., Hönack D., and Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J. Pharmacol. Exp. Ther. 284 (1998) 474-479
10. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., and Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 9861-9866
11. Margineanu D.-G., and Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol. Res. 42 (2000) 281-285
12. Margineanu D.G., and Klitgaard H. Can gap-junction blockade preferentially inhibit neuronal hypersynchrony vs. excitability?. Neuropharmacology 41 (2001) 377-383
13. Margineanu D.G., and Klitgaard H. Levetiracetam mechanisms of action. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Antiepileptic Drugs. 5th ed (2002), Lippincott, Williams & WIlkins, Philadelphia, PA 19106, USA 419-427
14. 2+ increase in rat cortical neurons in vitro. Epilepsia 50 4 (2009) 702-710
15. Matagne A., and Klitgaard H. Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man. Epilepsy Res. 31 (1998) 59-71
16. Matagne A., and Klitgaard H. Levetiracetam protects against seizures in fully hippocampal kindled rats. Epilepsia 40 Suppl 7 (1999) 137
17. Matagne A., Margineanu D.G., Kenda B., Michel P., and Klitgaard H. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br. J. Pharmacol. 154 (2008) 1662-1671
18. Noyer M., Gillard M., Matagne A., Henichart J.P., and Wulfert E. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur. J. Pharmacol. 286 (1995) 137-146
19. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1986), Academic Press, Australia
20. Racine R.J. Modification of seizure activity by electrical stimulation. II. Motor seizures. Electroencephalogr. Clin. Neurophysiol. 32 (1972) 281-294
21. Rigo J.-M., Nguyen L., Hans G., Belachew S., Moonen G., Matagne A., and Klitgaard H. Seletracetam (ucb 44212): effect on inhibitory and excitatory neurotransmission. Epilepsia 46 Suppl. 8 (2005) 110
22. + currents in rat brain neurons in vitro. Epilepsia 46 Suppl. 8 (2005) 116